Abstract

We evaluated the anti-influenza-virus effects of Melia components and discuss the utility of these components. The effects of leaf components of Melia azedarach L. on viruses were examined, and plaque inhibition tests were performed. The in vivo efficacy of M. azedarach L. was tested in a mouse model. Leaf components of Melia azedarach L. markedly inhibited the growth of various influenza viruses. In an initial screening, multiplication and haemagglutination (HA) activities of H1N1, H3N2, H5, and B influenza viruses were inactivated by the liquid extract of leaves of M. azedarach L. (MLE). Furthermore, plaque inhibition titres of H1N1, H3N2, and B influenza viruses treated with MLE ranged from 103.7 to 104.2. MLE possessed high plaque-inhibitory activity against pandemic avian H5N1, H7N9, and H9N2 vaccine candidate strains, with a plaque inhibition titre of more than 104.2. Notably, the buoyant density decreased from 1.175 to 1.137 g/cm3, and spikeless particles appeared. We identified four anti-influenza virus substances: pheophorbide b, pheophorbide a, pyropheophorbide a, and pheophytin a. Photomorphogenesis inside the envelope may lead to removal of HA and neuraminidase spikes from viruses. Thus, MLE could efficiently remove floating influenza virus in the air space without toxicity. Consistent with this finding, intranasal administration of MLE in mice significantly decreased the occurrence of pneumonia. Additionally, leaf powder of Melia (MLP) inactivated influenza viruses and viruses in the intestines of chickens. MLE and MLP may have applications as novel, safe biological disinfectants for use in humans and poultry.

Highlights

  • As an important respiratory disease, influenza may have the greatest impact of all known highly communicable diseases worldwide

  • To prevent virus infection and related complications caused by epidemic influenza viruses, e.g. H1N1, H3N2, and B influenza viruses, trivalent vaccines have been established to combat A (H1N1) pdm 09, H3N2 subtype, and B viruses [1]

  • Antigenic variation occurring in epidemic seasons frequently reduces the efficacy of seasonal inactivated or live vaccines in Japan and the United States of America (USA) [2, 3]

Read more

Summary

Introduction

As an important respiratory disease, influenza may have the greatest impact of all known highly communicable diseases worldwide. Antigenic variation occurring in epidemic seasons frequently reduces the efficacy of seasonal inactivated or live vaccines in Japan and the United States of America (USA) [2, 3]. In the USA, reduced vaccine efficacy was confirmed during the 2015–2016 season due to the antigenic gap between the A (H1N1) pdm vaccine strain and epidemic viruses. Recently developed neuraminidase inhibitors have played an important role in alleviating the symptoms of influenza infection; preventive efficacy has not yet been achieved [11]. Based on this information, novel and highly effective anti-influenza drugs are urgently needed. Jude Children Research Hospital, Memphis, TN, USA: RG-A/Barn Swallow/Hong Kong/1161/2010-A/PR/8/34 H5N1 [R] (6+2): (Swallow HK H5), RG-A/Anhui/2013-A/PR/8/34 H7N9 [R] (6+2): (Anhui H7), and A/Hong Kong/308/2014 -A/PR/8/34 H9N2 [R] (6+2): (HK H9)

Materials and methods
Results
Human strains
Discussion
Compliance with ethical standards
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call